<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/727DAA84-5778-46E5-AD06-516799EFA403"><gtr:id>727DAA84-5778-46E5-AD06-516799EFA403</gtr:id><gtr:name>Almac Group</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/727DAA84-5778-46E5-AD06-516799EFA403"><gtr:id>727DAA84-5778-46E5-AD06-516799EFA403</gtr:id><gtr:name>Almac Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A159BFCD-0A2C-4BC3-9CEA-573ACE508A6F"><gtr:id>A159BFCD-0A2C-4BC3-9CEA-573ACE508A6F</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>McElnay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12021"><gtr:id>4BB21E93-A02C-4724-9558-66627ACD9938</gtr:id><gtr:title>Confidence in Concept 2012 - Queen's University Belfast</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12021</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-08-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-02-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Almac Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of a biomarker for the SRC pathway in ovarian cancer</gtr:description><gtr:id>431D2B6E-63C2-4C0F-B247-611FBA223622</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>546372516fe916.73979444-1</gtr:outcomeId><gtr:partnerContribution>Commercialisation of the SRC biomarker may involve require a multi-centre prospective study for EOC patients in which treatment with a SRC inhibitor is selected on the basis of the SRC assay. Almac Diagnostics has extensive experience in these types of studies and is currently delivering the biomarker in 6 clinical trials for patient treatment selection. Funding for the validation study could be applied for through the MRC DPFS/DCS scheme or Invest Northern Ireland.</gtr:partnerContribution><gtr:piContribution>The clinical samples from the SAPPROC trial have all been received and a complete pathological review of the samples has been performed by Professor Glenn McCluggage (QUB). The samples are currently under-going DNA microarray analysis using a proprietary DNA microarray platform, the Ovarian Cancer DSA? array (Almac Diagnostics, Craigavon, UK). Correlations with signature score and response will then be made. It is anticipated that the results of this will be completed end of December 2014.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The utility of MN as a dosage form capable of reducing methotrexate side effects in children</gtr:description><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>1F104C79-81DD-4508-B48C-43173C2057E1</gtr:id><gtr:outcomeId>56e15d5f513625.11694808</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of EGFR-targeted camptothecin-loaded nanoparticles for targeting Kras wild-type colorectal cancer</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>267DF449-F170-4554-94FB-E5DAF39EA3DC</gtr:id><gtr:outcomeId>546372f2b6ed03.46347370</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>405000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Targeting treatment resistant cancer stem cells utilizing FKBPL-based therapeutic peptides; towards effective drug combination strategies for clinical trial.</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:id>7286AEDF-CB67-4F5D-AEAE-E102DEDAAB4C</gtr:id><gtr:outcomeId>546374f52e62b1.63669471</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>122000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sponsored research</gtr:description><gtr:fundingOrg>Proaxsis Ltd</gtr:fundingOrg><gtr:id>6EE8C58D-8461-449E-9298-6027D04D23BB</gtr:id><gtr:outcomeId>56e15b5865a4b6.65399573</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept - Development of thermo-sensitive growth factor delivering hydrogels incorporating calcium phosphate releasing nanoparticles for the targeted promotion of endochondral bone formation to facilitate strategic regeneration of bone-tissue int</gtr:description><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:id>815735E7-DFC6-4EC9-A66A-76F5FA958F15</gtr:id><gtr:outcomeId>54637124d11893.25002423</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>183000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Cystic Fibrosis Foundation Therapeutics</gtr:department><gtr:description>Protease-Tags: Development and Clinical Validation as Point-of-Care Diagnostics for Respiratory Disease</gtr:description><gtr:fundingOrg>Cystic Fibrosis Foundation</gtr:fundingOrg><gtr:id>DAD036C9-77DC-4592-8884-A05A6016A8FB</gtr:id><gtr:outcomeId>54637475a97e98.22012025</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>306000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Grant for R&amp;amp;D</gtr:description><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:id>B04E27F2-F292-4364-A6C5-9056FBCF4337</gtr:id><gtr:outcomeId>56e15c49ee6343.04707442</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3106000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Invest NI - Almac Collaboration</gtr:description><gtr:fundingOrg>NIS Ltd</gtr:fundingOrg><gtr:id>3FFFB75D-F350-472A-ACCB-1B6CE3EE3EDA</gtr:id><gtr:outcomeId>56e15a31305899.49398305</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine resiues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell del ivery system comprising the amph ipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules.</gtr:description><gtr:grantRef>MC_PC_12021</gtr:grantRef><gtr:id>F21BDBA7-F8E4-4A18-BC6B-27C2FDCB9E80</gtr:id><gtr:impact>The patent progressed to PCT and was published under WO2014087023, the patent was nationalised and is pending in the US and Europe. The technology has also been combined with WO2009040548 to achieve even greater effectiveness of delivery for vaccines.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c9164a81b101.06976031</gtr:outcomeId><gtr:patentId>WO2014087023</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>AN AMPHIPATHIC PEPTIDE</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.</gtr:description><gtr:grantRef>MC_PC_12021</gtr:grantRef><gtr:id>8018FDD1-FA3B-427A-AD55-A4A916A9252C</gtr:id><gtr:impact>The patent is now granted in the US, published under US9110163 B2 on 18 August 2015, and China, published under CN102428370B on 25/04/2012 and is pending in Europe. This project has informed the development of the FKBPL biomarker as a companion diagnostic for ALM201 and directly contributed to the filing of a US patent continuation on 16 July 2015 which includes methods to stratify patients response to ALM201 using the biomarker.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c91598e32c42.77120610</gtr:outcomeId><gtr:patentId>WO2010133880</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use.</gtr:description><gtr:grantRef>MC_PC_12021</gtr:grantRef><gtr:id>66E81FEC-EB1E-4E6C-A515-CF6BB363F78D</gtr:id><gtr:impact>.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c914d32fc4a5.63237436</gtr:outcomeId><gtr:patentId>WO2011024006</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOUND</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>ProAxsis Ltd</gtr:companyName><gtr:description>The work carried out in Dr Martin's CiC project in 2012, also attracted the early attention of AIM listed NetScientific plc, a healthcare medical technology company that commercialises research and technologies originating from leading universities. Working in partnership with NetScientific accelerated the formation of a new University spin-out venture called ProAxsis Ltd. The company has secured a range of investors including venture funding alongside Netscientific and others.</gtr:description><gtr:id>E5D24EA8-0EF6-4D73-A0CD-9905AEC049B5</gtr:id><gtr:impact>ProAxsis was named as one of Northern Ireland's most promising technology companies, winning the annual NISP Connect 25K awards in 2013 and recently secured funding from the first round of EU Horizon 2020 funding for small businesses.</gtr:impact><gtr:outcomeId>546375eb9f4fb7.11526762</gtr:outcomeId><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>AC80818B-333F-491B-89A6-BEAD96FE2E8B</gtr:id><gtr:title>Hierarchically Structured Electrospun Scaffolds with Chemically Conjugated Growth Factor for Ligament Tissue Engineering.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f5ff58310ab2a5c22fb0ef05e3cc09"><gtr:id>99f5ff58310ab2a5c22fb0ef05e3cc09</gtr:id><gtr:otherNames>Pauly HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>5aa69a6b9da104.18230388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0F14E97-822A-4151-9652-642F6954C98F</gtr:id><gtr:title>RALA complexed a-TCP nanoparticle delivery to mesenchymal stem cells induces bone formation in tissue engineered constructs in vitro and in vivo</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ee9f378b91028b2d2e36dcfc5cda6f2"><gtr:id>4ee9f378b91028b2d2e36dcfc5cda6f2</gtr:id><gtr:otherNames>Sathy B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050750X 20507518</gtr:issn><gtr:outcomeId>5aa69a6c234b80.28515605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0738BBC9-8660-460F-B7E4-24F8B62EEACC</gtr:id><gtr:title>Simple Radical Polymerization of Poly(Alginate-Graft-N-Isopropylacrylamide) Injectable Thermoresponsive Hydrogel with the Potential for Localized and Sustained Delivery of Stem Cells and Bioactive Molecules.</gtr:title><gtr:parentPublicationTitle>Macromolecular bioscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/384fa78b8d807c8dd9fe87458bc2f6f3"><gtr:id>384fa78b8d807c8dd9fe87458bc2f6f3</gtr:id><gtr:otherNames>Pentlavalli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1616-5187</gtr:issn><gtr:outcomeId>5aa69a6b596eb0.74647720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA82B53F-4F8B-4C3B-BFB2-44A896FF22AC</gtr:id><gtr:title>Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb5e167f9c4f242f6847ebad194f200e"><gtr:id>fb5e167f9c4f242f6847ebad194f200e</gtr:id><gtr:otherNames>Schmid D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>58c919eb7bbd49.73170016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE7C26A5-0C26-4009-94B6-756827D8E71B</gtr:id><gtr:title>Mechanical properties and cellular response of novel electrospun nanofibers for ligament tissue engineering: Effects of orientation and geometry.</gtr:title><gtr:parentPublicationTitle>Journal of the mechanical behavior of biomedical materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f5ff58310ab2a5c22fb0ef05e3cc09"><gtr:id>99f5ff58310ab2a5c22fb0ef05e3cc09</gtr:id><gtr:otherNames>Pauly HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1878-0180</gtr:issn><gtr:outcomeId>5aa69a6c62a336.55712275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67FE50BF-5EDF-4B3F-907E-A5BF62287A1B</gtr:id><gtr:title>Mesenchymal stem cell fate following non-viral gene transfection strongly depends on the choice of delivery vector.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5b3c354220fe676b2ce8ef943218189"><gtr:id>d5b3c354220fe676b2ce8ef943218189</gtr:id><gtr:otherNames>Gonzalez-Fernandez T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn><gtr:outcomeId>5aa69a6bdf2f11.61593775</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12021</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>